Skip to content

Upstream Bio, Inc. UPB Enterprise value

Enterprise value at other companies

Amgen logo
AmgenAMGN
$246.43B+9.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$427.4M+211%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$372.63M+3,155%
Savara logo
SavaraSVRA
$1.11B+127%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.35B+176%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s enterprise value?
Upstream Bio, Inc. (UPB) reported enterprise value of $394.17M in Q1 2026.
How has Upstream Bio, Inc.'s enterprise value changed year-over-year?
Upstream Bio, Inc.'s enterprise value increased by 52.4% year-over-year, from $258.67M to $394.17M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.